These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
369 related articles for article (PubMed ID: 33317255)
1. Persistence of intrahepatic hepatitis B virus DNA integration in patients developing hepatocellular carcinoma after hepatitis B surface antigen seroclearance. Jang JW; Kim JS; Kim HS; Tak KY; Nam H; Sung PS; Bae SH; Choi JY; Yoon SK; Roberts LR Clin Mol Hepatol; 2021 Jan; 27(1):207-218. PubMed ID: 33317255 [TBL] [Abstract][Full Text] [Related]
2. Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. Yoo S; Kim JY; Lim YS; Han S; Choi J J Hepatol; 2022 Oct; 77(4):939-946. PubMed ID: 35643206 [TBL] [Abstract][Full Text] [Related]
3. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Yuen MF; Wong DK; Sablon E; Tse E; Ng IO; Yuan HJ; Siu CW; Sander TJ; Bourne EJ; Hall JG; Condreay LD; Lai CL Hepatology; 2004 Jun; 39(6):1694-701. PubMed ID: 15185311 [TBL] [Abstract][Full Text] [Related]
4. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Yuen MF; Wong DK; Fung J; Ip P; But D; Hung I; Lau K; Yuen JC; Lai CL Gastroenterology; 2008 Oct; 135(4):1192-9. PubMed ID: 18722377 [TBL] [Abstract][Full Text] [Related]
5. Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss. Yip TC; Wong VW; Lai MS; Lai JC; Hui VW; Liang LY; Tse YK; Chan HL; Wong GL J Hepatol; 2023 Mar; 78(3):524-533. PubMed ID: 36463985 [TBL] [Abstract][Full Text] [Related]
6. Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance. Kim GA; Lee HC; Kim MJ; Ha Y; Park EJ; An J; Lee D; Shim JH; Kim KM; Lim YS J Hepatol; 2015 May; 62(5):1092-9. PubMed ID: 25445399 [TBL] [Abstract][Full Text] [Related]
7. A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance. Yang H; Bae SH; Nam H; Lee HL; Lee SW; Yoo SH; Song MJ; Kwon JH; Nam SW; Choi JY; Yoon SK; Jang JW J Hepatol; 2022 Sep; 77(3):632-641. PubMed ID: 35398462 [TBL] [Abstract][Full Text] [Related]
8. Clinical features of HBsAg seroclearance in hepatitis B virus carriers in South Korea: A retrospective longitudinal study. Park YM; Lee SG World J Gastroenterol; 2016 Nov; 22(44):9836-9843. PubMed ID: 27956808 [TBL] [Abstract][Full Text] [Related]
9. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899 [TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance. Fung J; Cheung KS; Wong DK; Mak LY; To WP; Seto WK; Lai CL; Yuen MF Hepatology; 2018 Aug; 68(2):462-472. PubMed ID: 29534307 [TBL] [Abstract][Full Text] [Related]
11. Hepatitis B virus (HBV) DNA integration in patients with occult HBV infection and hepatocellular carcinoma. Saitta C; Tripodi G; Barbera A; Bertuccio A; Smedile A; Ciancio A; Raffa G; Sangiovanni A; Navarra G; Raimondo G; Pollicino T Liver Int; 2015 Oct; 35(10):2311-7. PubMed ID: 25677098 [TBL] [Abstract][Full Text] [Related]
12. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. Liu J; Yang HI; Lee MH; Lu SN; Jen CL; Batrla-Utermann R; Wang LY; You SL; Hsiao CK; Chen PJ; Chen CJ; Gut; 2014 Oct; 63(10):1648-57. PubMed ID: 24225939 [TBL] [Abstract][Full Text] [Related]
13. What can we learn from hepatitis B virus clinical cohorts? Lin CL; Tseng TC; Kao JH Liver Int; 2015 Jan; 35 Suppl 1():91-9. PubMed ID: 25529093 [TBL] [Abstract][Full Text] [Related]
14. Among Patients with Undetectable Hepatitis B Surface Antigen and Hepatocellular Carcinoma, a High Proportion Has Integration of HBV DNA into Hepatocyte DNA and No Cirrhosis. Wong DK; Cheng SCY; Mak LL; To EW; Lo RC; Cheung TT; Seto WK; Fung J; Man K; Lai CL; Yuen MF Clin Gastroenterol Hepatol; 2020 Feb; 18(2):449-456. PubMed ID: 31252193 [TBL] [Abstract][Full Text] [Related]
16. Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. Yip TC; Chan HL; Wong VW; Tse YK; Lam KL; Wong GL J Hepatol; 2017 Nov; 67(5):902-908. PubMed ID: 28652084 [TBL] [Abstract][Full Text] [Related]
17. Systematic review with meta-analysis: development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance. Liu F; Wang XW; Chen L; Hu P; Ren H; Hu HD Aliment Pharmacol Ther; 2016 Jun; 43(12):1253-61. PubMed ID: 27117732 [TBL] [Abstract][Full Text] [Related]
18. Impact of AAV2 and Hepatitis B Virus Integration Into Genome on Development of Hepatocellular Carcinoma in Patients with Prior Hepatitis B Virus Infection. Tatsuno K; Midorikawa Y; Takayama T; Yamamoto S; Nagae G; Moriyama M; Nakagawa H; Koike K; Moriya K; Aburatani H Clin Cancer Res; 2019 Oct; 25(20):6217-6227. PubMed ID: 31320595 [TBL] [Abstract][Full Text] [Related]
19. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. Chu CM J Gastroenterol Hepatol; 2000 May; 15 Suppl():E25-30. PubMed ID: 10921378 [TBL] [Abstract][Full Text] [Related]
20. HBV DNA integration and HBV-transcript expression in non-B, non-C hepatocellular carcinoma in Japan. Tamori A; Nishiguchi S; Kubo S; Narimatsu T; Habu D; Takeda T; Hirohashi K; Shiomi S J Med Virol; 2003 Dec; 71(4):492-8. PubMed ID: 14556260 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]